Giampaolo Merlini

List of Publications by Year in Descending Order

644 papers	38,742 citations	97 h-index	181 g-index
747 ext. papers	46,615 ext. citations	5.1 avg, IF	7.27 L-index

#	Paper	IF	Citations
644	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.. *Circulation: Heart Failure*, **2022**, CIRCHEARTFAILURE121009038	7.6	0
643	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. *Blood*, **2021**, 138, 2720-2720	2.2	1
642	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. *Blood*, **2021**, 138, 4771-4771	2.2	
641	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. *Blood*, **2021**, 138, 153-153	2.2	2
640	Single Molecule Real-Time Sequencing of the M Protein (SMaRT M-Seq): Toward Personalized Medicine Approaches in Monoclonal Gammopathies. *Blood*, **2021**, 138, 2673-2673	2.2	
639	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. *Blood*, **2021**, 138, 2721-2721	2.2	1
638	Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. *Blood*, **2021**, 138, 2730-2730	2.2	0
637	Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. *Blood*, **2021**, 138, 159-159	2.2	1
636	Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma. *Blood*, **2021**, 138, 4725-4725	2.2	
635	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. *Blood Cancer Journal*, **2021**, 11, 192	7	10
634	Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. *Journal of Clinical Pharmacology*, **2021**,	2.9	1
633	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *British Journal of Haematology*, **2021**, 194, 496-507	4.5	12
632	Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. *Cells*, **2021**, 10,	7.9	10
631	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing Between Two Centres. *Molecules*, **2021**, 26,	4.8	2
630	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2021**, 42, 1554-1568	9.5	88
629	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Journal of Heart Failure*, **2021**, 23, 512-526	12.3	35
628	Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.. *Journal of Clinical Oncology*, **2021**, 39, 8003-8003	2.2	9

627	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. *European Journal of Clinical Investigation*, **2021**, 51, e13598	4.6	3
626	The Clinical Impact of Proteomics in Amyloid Typing. *Mayo Clinic Proceedings*, **2021**, 96, 1122-1127	6.4	2
625	Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). *Neurology and Therapy*, **2021**, 10, 753-766	4.6	3
624	A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. *Leukemia*, **2021**,	10.7	8
623	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. *Cardiology and Therapy*, **2021**, 10, 481-490	2.8	3
622	Search for AL amyloidosis risk factors using Mendelian randomization. *Blood Advances*, **2021**, 5, 2725-2731	7.18	3
621	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Circulation: Cardiovascular Imaging*, **2021**, 14, e000029	3.9	12
620	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Circulation: Cardiovascular Imaging*, **2021**, 14, e000030	3.9	6
619	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. *Frontiers in Medicine*, **2021**, 8, 668173	4.9	3
618	Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. *European Journal of Heart Failure*, **2021**, 23, 277-285	12.3	48
617	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. *Lancet Neurology, The*, **2021**, 20, 49-59	24.1	23
616	Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. *Journal of Neurology*, **2021**, 268, 2109-2122	5.5	61
615	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. *Blood Cancer Journal*, **2021**, 11, 34	7	19
614	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Journal of Cardiac Failure*, **2021**,	3.3	1
613	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. *New England Journal of Medicine*, **2021**, 385, 46-58	59.2	61
612	A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis. *Leukemia and Lymphoma*, **2021**, 1-7	1.9	1
611	Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. *FEBS Journal*, **2021**,	5.7	10
610	Age-related amyloidosis outside the brain: A state-of-the-art review. *Ageing Research Reviews*, **2021**, 70, 101388	12	4

609	How I Treat AL Amyloidosis. *Blood*, **2021**,	2.2	2
608	In search of the most effective therapy for light chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2021**, 1-2	2.7	1
607	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS. *JACC: Heart Failure*, **2021**, 9, 736-746	7.9	7
606	Future Perspectives. *Hematology/Oncology Clinics of North America*, **2020**, 34, 1205-1214	3.1	1
605	Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. *Blood*, **2020**, 135, 293-296	2.2	13
604	A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. *Blood*, **2020**, 135, 1531-1540	2.2	59
603	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. *British Journal of Haematology*, **2020**, 190, 346-357	4.5	8
602	Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 231-236	2.7	9
601	Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years. *Neurology and Therapy*, **2020**, 9, 105-115	4.6	12
600	A powerful oral triplet for AL amyloidosis. *British Journal of Haematology*, **2020**, 189, 605-606	4.5	1
599	Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. *European Journal of Neurology*, **2020**, 27, 1374-1381	6	23
598	Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 168-173	2.7	5
597	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey. *Blood*, **2020**, 136, 11-11	2.2	
596	The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis. *Blood*, **2020**, 136, 22-22	2.2	0
595	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. *Blood*, **2020**, 136, 33-34	2.2	
594	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. *Blood*, **2020**, 136, 48-50	2.2	7
593	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. *Blood*, **2020**, 136, 44-45	2.2	2
592	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. *Blood*, **2020**, 136, 6-7	2.2	2

591	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. *Blood*, **2020**, 136, 50-51	2.2	4
590	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. *Blood*, **2020**, 136, 71-80	2.2	86
589	Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. *Blood Advances*, **2020**, 4, 1321-1324	7.8	13
588	Ixazomib-dexamethasone (Ixa-Dex) vs physician choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. *Journal of Clinical Oncology*, **2020**, 38, 8546-8546	2.2	5
587	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. *Leukemia*, **2020**, 34, 1187-1191	10.7	12
586	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 97-102	2.7	14
585	Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains. *Journal of Molecular Biology*, **2020**, 432, 845-860	6.5	10
584	Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. *Journal of Neurology*, **2020**, 267, 1070-1079	5.5	12
583	Amyloidosis and Ocular Involvement: an Overview. *Seminars in Ophthalmology*, **2020**, 35, 7-26	2.4	12
582	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). *Blood Cancer Journal*, **2020**, 10, 102	7	45
581	Management of AL amyloidosis in 2020. *Blood*, **2020**, 136, 2620-2627	2.2	44
580	Management of AL amyloidosis in 2020. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 363-371	3.1	16
579	Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. *Frontiers in Pharmacology*, **2020**, 11, 1024	5.6	10
578	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. *Journal of Clinical Oncology*, **2020**, 38, 3252-3260	2.2	41
577	Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside. *Expert Review of Hematology*, **2020**, 13, 1003-1015	2.8	4
576	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 259-265	2.7	25
575	Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 217-222	2.7	123
574	Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. *Journal of Biological Chemistry*, **2020**, 295, 16572-16584	5.4	13

573	Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. *Blood Cancer Journal*, **2020**, 10, 90	7	11
572	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. *BMC Family Practice*, **2020**, 21, 198	2.6	23
571	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. *Mediators of Inflammation*, **2020**, 2020, 8562485	4.3	13
570	Redirecting proteoxicity. *Leukemia*, **2020**, 34, 3109-3110	10.7	
569	Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. *Blood Advances*, **2020**, 4, 4175-4179	7.8	10
568	High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. *American Journal of Hematology*, **2020**, 95, 900-905	7.1	15
567	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. *Blood Cancer Journal*, **2020**, 10, 41	7	16
566	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. *Circulation: Heart Failure*, **2019**, 12, e006075	7.6	171
565	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Journal of Cardiac Failure*, **2019**, 25, 854-865	3.3	40
564	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Journal of Cardiac Failure*, **2019**, 25, e1-e39	3.3	56
563	Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 10-14	2.7	8
562	ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. *Analytical Chemistry*, **2019**, 91, 2894-2900	7.8	18
561	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. *BMC Medical Genetics*, **2019**, 20, 23	2.1	6
560	Human osteogenic differentiation in Space: proteomic and epigenetic clues to better understand osteoporosis. *Scientific Reports*, **2019**, 9, 8343	4.9	19
559	A revised international prognostic score system for Waldenstrm's macroglobulinemia. *Leukemia*, **2019**, 33, 2654-2661	10.7	27
558	Treatment of cardiac transthyretin amyloidosis: an update. *European Heart Journal*, **2019**, 40, 3699-3706	9.5	75
557	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. *JAMA Cardiology*, **2019**, 4, 466-472	16.2	40
556	Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. *American Journal of Physiology - Heart and Circulatory Physiology*, **2019**, 316, H1158-H1166	5.2	12

555	Stabilization of amyloidogenic immunoglobulin light chains by small molecules. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 8360-8369	11.5	30
554	Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. *Nature Communications*, **2019**, 10, 1269	17.4	68
553	Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. *Leukemia*, **2019**, 33, 254-257	10.7	40
552	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. *Blood*, **2019**, 134, 320-323	2.2	4
551	Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 105-106	2.7	2
550	The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 107-108	2.7	2
549	Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. *BMJ Open*, **2019**, 9, e025483	3	9
548	OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis. *Blood*, **2019**, 134, 3163-3163	2.2	3
547	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). *Blood*, **2019**, 134, 139-139	2.2	29
546	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. *Blood*, **2019**, 134, 3166-3166	2.2	15
545	The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy. *Blood*, **2019**, 134, 1901-1901	2.2	2
544	Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. *Blood*, **2019**, 134, 3066-3066	2.2	0
543	Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN). *Blood*, **2019**, 134, 1868-1868	2.2	0
542	Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis. *Blood* , **2019**, 134, 1860-1860	2.2	0
541	Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis. *Blood*, **2019**, 134, 3312-3312	2.2	0
540	PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY. *HemaSphere*, **2019**, 3, 234-235	0.3	
539	PS1221 LONG-TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEURO-TTR OPEN-LABEL EXTENSION 2-YEAR UPDATE. *HemaSphere*, **2019**, 3, 557	0.3	1
538	When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. *Blood Advances*, **2019**, 3, 212-215	7.8	18

537	A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e40-e41	2	3
536	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. *HemaSphere*, **2019**, 3, 616	0.3	0
535	High sensitivity M-protein detection in a case of light-chain cardiac amyloidosis without evidence of plasma cell dyscrasia. *American Journal of Hematology*, **2019**, 94, 619-621	7.1	1
534	Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice. *Kidney International*, **2019**, 95, 258-260	9.9	4
533	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. *Circulation*, **2019**, 139, 431-443	16.7	180
532	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nature Reviews Nephrology*, **2019**, 15, 45-59	14.9	189
531	Light Chain Amyloidosis. *Mediterranean Journal of Hematology and Infectious Diseases*, **2018**, 10, e2018022	3.2	37
530	The elusive pathogenesis of Schnitzler syndrome. *Blood*, **2018**, 131, 944-946	2.2	7
529	Waldenström Macroglobulinemia. *Hematologic Malignancies*, **2018**, 191-220	0	1
528	Primary Systemic Amyloidosis. *Hematologic Malignancies*, **2018**, 221-245	0	
527	Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing. *Proteomics*, **2018**, 18, e1700353	4.8	3
526	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. *Blood*, **2018**, 131, 1568-1575	2.2	35
525	Novel Therapies in Light Chain Amyloidosis. *Kidney International Reports*, **2018**, 3, 530-541	4.1	16
524	New concepts in the treatment and diagnosis of amyloidosis. *Expert Review of Hematology*, **2018**, 11, 117-127	2.8	13
523	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia*, **2018**, 32, 1883-1898	10.7	58
522	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma **2018**, 1419-1431.e5		
521	Waldenström Macroglobulinemia **2018**, 617-638		
520	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. *Blood*, **2018**, 132, 1478-1485	2.2	93

519	Outrageous prices of orphan drugs: a call for collaboration. *Lancet, The*, **2018**, 392, 791-794	40	69
518	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circulation: Cardiovascular Imaging*, **2018**, 11, e006588	3.9	31
517	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. *Journal of Hematology and Oncology*, **2018**, 11, 10	22.4	89
516	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *New England Journal of Medicine*, **2018**, 379, 1007-1016	59.2	859
515	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. *Blood*, **2018**, 132, 1988-1991	2.2	20
514	MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. *American Journal of Hematology*, **2018**, 93, E368-E370	7.1	26
513	Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis. *Blood*, **2018**, 132, 498-498	2.2	1
512	Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial. *Blood*, **2018**, 132, 4803-4803	2.2	1
511	Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial. *Blood*, **2018**, 132, 4812-4812	2.2	1
510	Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome. *Blood*, **2018**, 132, 2026-2026	2.2	0
509	Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients. *Blood*, **2018**, 132, 3264-3264	2.2	
508	Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab. *Blood*, **2018**, 132, 1985-1985	2.2	
507	Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. *Blood*, **2018**, 131, 525-532	2.2	35
506	Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2018**, 25, 215-219	2.7	278
505	Systemic immunoglobulin light chain amyloidosis. *Nature Reviews Disease Primers*, **2018**, 4, 38	51.1	207
504	Therapies for cardiac light chain amyloidosis: An update. *International Journal of Cardiology*, **2018**, 271, 152-160	3.2	15
503	Management of the elderly patient with AL amyloidosis. *European Journal of Internal Medicine*, **2018**, 58, 48-56	3.9	13
502	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. *New England Journal of Medicine*, **2018**, 379, 22-31	59.2	618

501	Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 439-445	12.7	50
500	Assessing mNIS+7 and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. *Muscle and Nerve*, **2017**, 56, 901-911	3.4	35
499	Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage. *Antioxidants and Redox Signaling*, **2017**, 27, 567-582	8.4	28
498	The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. *Blood*, **2017**, 129, 2132-2142	2.2	55
497	A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. *Blood*, **2017**, 129, 2120-2123	2.2	66
496	Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 457-458	5.5	59
495	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. *British Journal of Haematology*, **2017**, 176, 728-742	4.5	34
494	Regulated expression of amyloidogenic immunoglobulin light chains in mice. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 52-53	2.7	3
493	Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 66-67	2.7	3
492	The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. *American Journal of Hematology*, **2017**, 92, 772-779	7.1	71
491	Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 54-55	2.7	2
490	Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 68-69	2.7	4
489	Prognostication of survival and progression to dialysis in AA amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 136-137	2.7	4
488	Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 56-57	2.7	9
487	Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 60-61	2.7	2
486	Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 64-65	2.7	5
485	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). *Circulation: Heart Failure*, **2017**, 10,	7.6	48
484	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. *Blood*, **2017**, 130, 597-605	2.2	89

483	Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. *Blood*, **2017**, 130, 625-631	2.2	86
482	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1734-1743	5.9	24
481	Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. *Leukemia*, **2017**, 31, 1735-1742	10.7	32
480	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. *Blood*, **2017**, 129, 456-459	2.2	40
479	Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 1095-1110	6.4	17
478	AL amyloidosis: from molecular mechanisms to targeted therapies. *Hematology American Society of Hematology Education Program*, **2017**, 2017, 1-12	3.1	77
477	Systemic amyloidosis: novel therapies and role of biomarkers. *Nephrology Dialysis Transplantation*, **2017**, 32, 770-780	4.3	33
476	Attitudes about when and how to treat patients with AL amyloidosis: an international survey. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 213-216	2.7	24
475	The lung in amyloidosis. *European Respiratory Review*, **2017**, 26,	9.8	64
474	Persistence of Minimal Residual Disease by Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients With AL Amyloidosis. *Clinical Lymphoma, Myeloma and Leukemia*, **2017** , 17, e24	2	2
473	Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. *Scientific Reports*, **2017**, 7, 15661	4.9	37
472	Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. *British Journal of Haematology*, **2017**, 179, 748-755	4.5	37
471	Cardiac light-chain deposition disease relapsing in the transplanted heart. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 135-137	2.7	1
470	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. *Haematologica*, **2017**, 102, e411-e414	6.6	7
469	Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system. *Journal of Neuroinflammation*, **2017**, 14, 115	10.1	12
468	Unusual Manifestations of IgM Monoclonal Gammopathies **2017**, 223-236		
467	Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity. *Scientific Reports*, **2017**, 7, 16809	4.9	31
466	Kidney Involvement in Light Chain Amyloidosis. *Journal of Onco-Nephrology*, **2017**, 1, 110-119	0.2	1

465	Monoclonal IgM-related AL amyloidosis. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 241-248	4.2	23
464	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 1129-1134	7.1	42
463	Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2016**, 23, 209-213	2.7	369
462	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. *British Journal of Haematology*, **2016**, 175, 77-86	4.5	41
461	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. *Journal of Clinical Oncology*, **2016**, 34, 2037-45	2.2	46
460	Clinical Pregenetic Screening for Stroke Monogenic Diseases: Results From Lombardia GENS Registry. *Stroke*, **2016**, 47, 1702-9	6.7	27
459	Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. *Journal of Leukocyte Biology*, **2016**, 99, 761-9	6.5	14
458	The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 939-45	5.9	8
457	Systemic amyloidoses and proteomics: The state of the art. *EuPA Open Proteomics*, **2016**, 11, 4-10	0.1	11
456	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. *Neurology and Therapy*, **2016**, 5, 1-25	4.6	91
455	Monitoring free light chains in serum using mass spectrometry. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1073-83	5.9	24
454	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. *Journal of Clinical Oncology*, **2016**, 34, 1097-103	2.2	141
453	Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 921-7	5.9	9
452	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. *Journal of Clinical Oncology*, **2016**, 34, 1544-57	2.2	204
451	A patient with AL amyloidosis with negative free light chain results. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1035-7	5.9	6
450	Patterns of Relapse after Upfront Therapy in AL Amyloidosis. *Blood*, **2016**, 128, 2140-2140	2.2	2
449	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. *Blood*, **2016**, 128, 2957-2957	2.2	1
448	Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response. *Blood*, **2016**, 128, 3261-3261	2.2	20

447	The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction. *Blood*, **2016**, 128, 5690-5690	2.2	3
446	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. *Blood*, **2016**, 128, 646-646	2.2	32
445	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. *Blood*, **2016**, 128, 648-648	2.2	1
444	The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction.. *Journal of Clinical Oncology*, **2016**, 34, TPS8073-TPS8073	2.2	1
443	In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. *Scientific Reports*, **2016**, 6, 29096	4.9	40
442	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*, **2016**, 133, 2404-12	16.7	792
441	What is new in diagnosis and management of light chain amyloidosis?. *Blood*, **2016**, 128, 159-68	2.2	134
440	Treatment recommendations from the Eighth International Workshop on Waldenstrm's Macroglobulinemia. *Blood*, **2016**, 128, 1321-8	2.2	125
439	Advances in proteomic study of cardiac amyloidosis: progress and potential. *Expert Review of Proteomics*, **2016**, 13, 1017-1027	4.2	3
438	Immunoglobulin Light Chain Systemic Amyloidosis. *Cancer Treatment and Research*, **2016**, 169, 273-318	3.5	17
437	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. *Leukemia*, **2016**, 30, 1979-1986	10.7	52
436	Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney. *Kidney International*, **2016**, 90, 479-81	9.9	9
435	Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2016**, 245, S113-8	2	5
434	Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium. *Journal of Cardiac Failure*, **2015**, 21, S63	3.3	2
433	Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. *Neurology*, **2015**, 85, 675-82	6.5	83
432	Rare diseases and effective treatments: are we delivering?. *Lancet, The*, **2015**, 385, 750-2	40	32
431	Novel strategies for the diagnosis and treatment of cardiac amyloidosis. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 1195-211	2.5	24
430	Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. *FASEB Journal*, **2015**, 29, 4614-28	0.9	43

429	Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. *Nutrition*, **2015**, 31, 1228-34	4.8	19
428	Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. *Journal of the American College of Cardiology*, **2015**, 66, 2451-2466	15.1	250
427	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e59-e60	2	6
426	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2015**, 22, 187-93	2.7	3
425	A practical approach to the diagnosis of systemic amyloidoses. *Blood*, **2015**, 125, 2239-44	2.2	120
424	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood*, **2015**, 126, 612-5	2.2	232
423	Enlightening light chain deposition disease. *Blood*, **2015**, 126, 2770-1	2.2	6
422	Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. *Advances in Therapy*, **2015**, 32, 920-8	4.1	131
421	Serum markers of myocardial damage in acute pancreatitis: a prospective time course study. *Pancreas*, **2015**, 44, 678-80	2.6	2
420	The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-B pathway. *Arthritis Research and Therapy*, **2015**, 17, 93	5.7	32
419	Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. *Kidney International*, **2015**, 87, 1223-9	9.9	20
418	Etiology of amyloidosis determines myocardial 99mTc-DPD uptake in amyloidotic cardiomyopathy. *Clinical Nuclear Medicine*, **2015**, 40, 446-7	1.7	6
417	Diagnosis of monoclonal gammopathy of renal significance. *Kidney International*, **2015**, 87, 698-711	9.9	261
416	Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome. *Blood*, **2015**, 126, 1773-1773	2.2	2
415	Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients. *Blood*, **2015**, 126, 190-190	2.2	2
414	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. *Current Clinical Pathology*, **2015**, 9-29	0.1	3
413	The Role of Differential Proteomics in Amyloid Typing: The Experience of the Pavia Referral Center. *Current Clinical Pathology*, **2015**, 323-330	0.1	
412	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). *Blood*, **2015**, 126, 3292-3292	2.2	

411	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). *Leukemia*, **2014**, 28, 525-42	10.7	179
410	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. *Leukemia*, **2014**, 28, 2311-6	10.7	97
409	Hereditary apolipoprotein A1 amyloidosis with cutaneous and cardiac involvement: a long familial history. *European Journal of Dermatology*, **2014**, 24, 261-3	0.8	1
408	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology, The*, **2014**, 15, e538-48	21.7	2253
407	Waldenstrm macroglobulinemia. *Hematology/Oncology Clinics of North America*, **2014**, 28, 945-70	3.1	19
406	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. *Haematologica*, **2014**, 99, 743-50	6.6	109
405	Determining the significance of MGUS. *Blood*, **2014**, 123, 305-7	2.2	6
404	A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. *Blood*, **2014**, 123, 3543-52	2.2	97
403	Treatment recommendations for patients with Waldenstrm macroglobulinemia (WM) and related disorders: IWWM-7 consensus. *Blood*, **2014**, 124, 1404-11	2.2	107
402	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. *Blood*, **2014**, 124, 2498-506	2.2	49
401	A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. *Blood*, **2014**, 124, 2325-32	2.2	265
400	Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. *Journal of Hypertension*, **2014**, 32, 1121-31; discussion 1131	1.9	17
399	Immunoglobulin light chain amyloidosis. *Expert Review of Hematology*, **2014**, 7, 143-56	2.8	83
398	Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans. *Worm*, **2014**, 3, e965590		5
397	Pathogenesis of renal failure in multiple myeloma: any role of contrast media?. *BioMed Research International*, **2014**, 2014, 167125	3	12
396	An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. *Expert Opinion on Investigational Drugs*, **2014**, 23, 1239-51	5.9	40
395	IMWG consensus on risk stratification in multiple myeloma. *Leukemia*, **2014**, 28, 269-77	10.7	387
394	The red cell distribution width (RDW): value and role in preterm, IUGR (intrauterine growth restricted), full-term infants. *Hematology*, **2014**, 19, 365-9	2.2	19

393	Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. *Expert Review of Molecular Diagnostics*, **2014**, 14, 55-66	3.8	26
392	Biochemical markers in early diagnosis and management of systemic amyloidoses. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 1517-31	5.9	18
391	Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment. *Journal of Parenteral and Enteral Nutrition*, **2014**, 38, 891-4	4.2	12
390	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. *Seminars in Arthritis and Rheumatism*, **2014**, 43, 818-23	5.3	62
389	Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). *Blood*, **2014**, 124, 3450-3450	2.2	16
388	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. *Blood*, **2014**, 124, 35-35	2.2	10
387	A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. *Blood*, **2014**, 124, 305-305	2.2	
386	Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome. *Blood*, **2014**, 124, 3361-3361	2.2	
385	Waldenström Macroglobulinemia **2014**, 303-329		
384	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2013**, 20, 142-50	2.7	84
383	TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. *Neurological Sciences*, **2013**, 34, 1057-63	3.5	38
382	Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. *Annals of Hematology*, **2013**, 92, 1133-4	3	2
381	Systemic amyloidoses: what an internist should know. *European Journal of Internal Medicine*, **2013**, 24, 729-39	3.9	22
380	Serum prealbumin: an independent marker of short-term energy intake in the presence of multiple-organ disease involvement. *Nutrition*, **2013**, 29, 580-2	4.8	24
379	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. *Journal of Clinical Oncology*, **2013**, 31, 2347-57	2.2	245
378	Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. *Journal of Cardiovascular Translational Research*, **2013**, 6, 1011-20	3.2	109
377	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2013**, 20, 173-8	2.7	20
376	High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2013**, 20, 48-51	2.7	10

375	Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). *Blood*, **2013**, 122, 3276-82	2.2	135
374	Response assessment in Waldenstrm macroglobulinaemia: update from the VIth International Workshop. *British Journal of Haematology*, **2013**, 160, 171-6	4.5	173
373	Clinical proteomics for diagnosis and typing of systemic amyloidoses. *Proteomics - Clinical Applications*, **2013**, 7, 136-43	3.1	29
372	Diagnostic challenges of amyloidosis in Waldenstrm macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 244-6	2	9
371	Prognostic value of fragmented QRS in cardiac AL amyloidosis. *International Journal of Cardiology*, **2013**, 167, 2156-61	3.2	36
370	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. *Leukemia*, **2013**, 27, 780-91	10.7	222
369	Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. *Journal of Proteome Research*, **2013**, 12, 5642-55	5.6	42
368	Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. *Basic Research in Cardiology*, **2013**, 108, 378	11.8	44
367	Late onset cardiomyopathy due to transthyretin Ile68Leu mutation: a cardiogenic variant of familial amyloidosis potentially mimicking sarcomeric hypertrophic cardiomyopathy. *European Heart Journal*, **2013**, 34, P2958-P2958	9.5	
366	The role of gender and age in cardiac AL amyloidosis. *European Heart Journal*, **2013**, 34, P2996-P2996	9.5	
365	Is a restrictive LV filling pattern invariably present in restrictive cardiomyopathy? The case of cardiac AL amyloidosis. *European Heart Journal*, **2013**, 34, P2442-P2442	9.5	
364	An ECG/ECHO comparison between AL and ATTR cardiac amyloidosis at diagnosis. *European Heart Journal*, **2013**, 34, P2991-P2991	9.5	1
363	Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality. *European Heart Journal*, **2013**, 34, P4239-P4239	9.5	
362	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. *European Heart Journal*, **2013**, 34, 520-8	9.5	181
361	Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. *American Journal of Physiology - Heart and Circulatory Physiology*, **2013**, 305, H95-103	5.2	95
360	Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2013**, 310, 2658-67	27.4	424
359	Recommendations for appropriate serum electrophoresis requests: the Italian approach. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, e117-8	5.9	1
358	Reply to S. Girnius et al. *Journal of Clinical Oncology*, **2013**, 31, 2750-1	2.2	1

357	Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. *Annals of Noninvasive Electrocardiology*, **2013**, 18, 271-80	1.5	55
356	Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. *Annals of Noninvasive Electrocardiology*, **2013**, 18, 327-35	1.5	28
355	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. *Blood*, **2013**, 121, 3420-7	2.2	267
354	Systemic light chain amyloidosis: an update for treating physicians. *Blood*, **2013**, 121, 5124-30	2.2	171
353	A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. *Haematologica*, **2013**, 98, 433-6	6.6	61
352	THU0376 Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). *Annals of the Rheumatic Diseases*, **2013**, 71, 282.3-283	2.4	1
351	Diagnostic performance of triggering receptor expressed on myeloid cells-1 and CD64 index as markers of sepsis in preterm newborns. *Pediatric Critical Care Medicine*, **2013**, 14, 178-82	3	19
350	First Line Therapy With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem Cell Transplant. *Blood*, **2013**, 122, 1985-1985	2.2	1
349	High-Dose Pomalidomide and Dexamethasone Induce Rapid Responses In Patients With AL Amyloidosis Exposed To Alkylators, Immune Modulatory Drugs, and Proteasome Inhibitors. *Blood*, **2013**, 122, 288-288	2.2	2
348	First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). *PLoS ONE*, **2013**, 8, e73443	3.7	37
347	A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli. *PLoS ONE*, **2013**, 8, e76022	3.7	17
346	Amiloidosi **2013**, 127-131		
345	Waldenstrm Macroglobulinemia/Lymphoplasmacytic Lymphoma **2013**, 83-109		
344	Identification Of Reversible Organ Damage and Of Early Markers Of Response To Treatment In Renal AL Amyloidosis: A Study On 461 Patients. *Blood*, **2013**, 122, 3087-3087	2.2	
343	Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. *American Journal of Hematology*, **2012**, 87, 465-71	7.1	70
342	Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. *Annals of Hematology*, **2012**, 91, 89-92	3	70
341	Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. *Annals of Hematology*, **2012**, 91, 399-406	3	27
340	The repertoire of light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. *Blood*, **2012**, 119, 144-50	2.2	79

339	Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. *Blood*, **2012**, 119, 1844-7	2.2	133
338	CyBorD: stellar response rates in AL amyloidosis. *Blood*, **2012**, 119, 4343-5	2.2	43
337	Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2012**, 19, 167-70	2.7	193
336	New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *Journal of Clinical Oncology*, **2012**, 30, 4541-9	2.2	553
335	Amyloidosis in autoinflammatory syndromes. *Autoimmunity Reviews*, **2012**, 12, 14-7	13.6	79
334	Characterization for anti-cytoplasmic antibodies specificity by morphological and molecular techniques. *Autoimmunity Highlights*, **2012**, 3, 79-85	3.7	8
333	Risk stratification in Waldenstrm macroglobulinemia. *Expert Review of Hematology*, **2012**, 5, 187-99	2.8	12
332	Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide. *Clinica Chimica Acta*, **2012**, 413, 544-7	6.2	13
331	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580
330	The Diflunisal Trial: study accrual and drug tolerance. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2012**, 19 Suppl 1, 37-8	2.7	34
329	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2012**, 19 Suppl 1, 34-6	2.7	147
328	Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. *Canadian Journal of Cardiology*, **2012**, 28, 537-41	3.8	23
327	Management of treatment-emergent peripheral neuropathy in multiple myeloma. *Leukemia*, **2012**, 26, 595-608	10.7	189
326	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. *Leukemia*, **2012**, 26, 2317-25	10.7	247
325	Differential diagnosis of monoclonal gammopathy of undetermined significance. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 595-603	3.1	64
324	Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. *Stem Cells*, **2012**, 30, 1465-76	5.8	46
323	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. *Annals of Hematology*, **2012**, 91, 875-88	3	27
322	Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. *Nephrology Dialysis Transplantation*, **2012**, 27, 3713-8	4.3	25

321	Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2012**, 19 Suppl 1, 11-3	2.7	6
320	Differential diagnosis of monoclonal gammopathy of undetermined significance. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 595-603	3.1	28
319	Use of the Novel Monoclonal Assay for the Measurement of Circulating Free Light Chain in the Diagnosis, Prognostication of Survival and Assessment of Response to Therapy in AL Amyloidosis. *Blood*, **2012**, 120, 3913-3913	2.2	3
318	Treatment of AL Amyloidosis with Bendamustine. *Blood*, **2012**, 120, 4057-4057	2.2	4
317	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. *Blood*, **2012**, 120, 731-731	2.2	11
316	Transthyretin-associated Familial Amyloid Polyneuropathy - Current and Emerging Therapies. *European Neurological Review*, **2012**, 7, 14	0.5	2
315	AA amyloidosis: basic knowledge, unmet needs and future treatments. *Swiss Medical Weekly*, **2012**, 142, w13580	3.1	66
314	Amyloid Typing: Immunoelectron Microscopy **2012**, 249-260		1
313	Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case Study. *Lecture Notes in Computer Science*, **2012**, 65-79	0.9	4
312	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis **2012**, 9-29		
311	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. *Blood*, **2012**, 120, 4074-4074	2.2	1
310	Severity in biliary peritonitis. *Giornale Di Chirurgia*, **2012**, 33, 168-71	2.2	2
309	The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 80-2	2.7	44
308	Can ISSWM be used for making treatment decisions?. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 121-3	2	2
307	Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 143-5	2	26
306	Amyloidosis: pathogenesis and new therapeutic options. *Journal of Clinical Oncology*, **2011**, 29, 1924-33	2.2	349
305	The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18, 191-9	2.7	15
304	Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. *Clinica Chimica Acta*, **2011**, 412, 1262-5	6.2	14

303	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011**, 1812, 87-93	6.9	21
302	Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. *Journal of Molecular Biology*, **2011**, 407, 465-76	6.5	42
301	Transplantation vs. conventional-dose therapy for amyloidosis. *Current Opinion in Oncology*, **2011**, 23, 214-20	4.2	29
300	Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. *Blood*, **2011**, 118, 865-73	2.2	141
299	Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. *Journal of the Peripheral Nervous System*, **2011**, 16, 119-29	4.7	60
298	AMICA: an electronic patient record specifically designed for an amyloidosis network. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 236-8	2.7	
297	Beta2-microglobulin causes abnormal phosphatidylserine exposure in human red blood cells. *Molecular BioSystems*, **2011**, 7, 651-8		9
296	Amyloidosis presenting with Fabry disease. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 231-2	2.7	1
295	Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 96-7	2.7	3
294	Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 64-6	2.7	13
293	The diflunisal trial: update on study drug tolerance and disease progression. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 196-7	2.7	19
292	A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2011**, 1814, 409-19	4	34
291	Reducing the amyloid burden through immunotherapy: a major therapeutic advance. *Nephrology Dialysis Transplantation*, **2011**, 26, 1471-3	4.3	1
290	Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 61-3	2.7	4
289	Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18, 87-90	2.7	13
288	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. *QJM - Monthly Journal of the Association of Physicians*, **2011**, 104, 957-70	2.7	37
287	A workflow management system for the biological samples exchange within the amyloidosis network. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 233-5	2.7	
286	Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18, 216-21	2.7	22

285	Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* **2011**, 18 Suppl 1, 92-3	2.7	20
284	Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. *Annals of the Rheumatic Diseases*, **2011**, 70, 1511-2	2.4	69
283	Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients,. *Blood*, **2011**, 118, 3977-3977	2.2	2
282	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. *Blood*, **2011**, 118, 995-995	2.2	3
281	Pilot Study with Lenalidomide in Patients with POEMS Syndrome. *Blood*, **2011**, 118, 4612-4612	2.2	
280	Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. *Oncology*, **2011**, 25, 633, 637-8	1.8	1
279	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*, **2010**, 24, 1121-7	10.7	505
278	Characterization of the new serum protein reference material ERM-DA470k/IFCC: value assignment by immunoassay. *Clinical Chemistry*, **2010**, 56, 1880-8	5.5	60
277	Systemic diseases: from amyloidosis to cryoglobulinemia. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 1912-5	6.9	1
276	Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. *Journal of Clinical Oncology*, **2010**, 28, 1031-7	2.2	226
275	Standardizing plasma protein measurements worldwide: a challenging enterprise. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1567-75	5.9	26
274	Development and preparation of a new serum protein reference material: feasibility studies and processing. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 805-13	5.9	15
273	Embryonic stem and haematopoietic progenitor cells resist to A□oligomer toxicity and maintain the differentiation potency in culture. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2010**, 17, 137-45	2.7	3
272	Multiple myeloma. *Annals of Oncology*, **2010**, 21 Suppl 7, vii143-50	10.3	62
271	Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2010**, 17, 101-4	2.7	252
270	Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. *Journal of Translational Medicine*, **2010**, 8, 74	8.5	124
269	The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. *Blood*, **2010**, 116, 3426-30	2.2	159
268	Monoclonal gammopathies. *BMC Geriatrics*, **2010**, 10,	4.1	78

267	FISH reveals chromosomal abnormalities in 41 Patients with Systemic Amyloidosis (AL).. *Blood*, **2010**, 116, 1197-1197	2.2	1
266	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. *Blood*, **2010**, 116, 1364-1364	2.2	15
265	Assessing Proteostasis and Proteasome Stress In Light Chain Amyloidosis. *Blood*, **2010**, 116, 3992-3992	2.2	2
264	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. *Blood*, **2010**, 116, 988-988	2.2	4
263	Imaging of Systemic Amyloidosis **2010**, 15-32		5
262	Pathogenesis of Systemic Amyloidoses **2010**, 49-64		
261	Primary Therapy of Waldenstro m's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. *Blood*, **2010**, 116, 1941-1941	2.2	3
260	Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib. *Blood*, **2010**, 116, 3062-3062	2.2	
259	Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. *Clinical Chemistry*, **2009**, 55, 499-504	5.5	169
258	Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2009**, 16, 115-21	2.7	2
257	Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. *Journal of Clinical Oncology*, **2009**, 27, 120-6	2.2	173
256	A multi-fpga 10x-real-time high-speed search engine for a 5000-word vocabulary speech recognizer **2009**,		15
255	Proteomics in protein misfolding diseases. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 627-35	5.9	8
254	Current treatment of AL amyloidosis. *Haematologica*, **2009**, 94, 1044-8	6.6	43
253	Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. *Circulation*, **2009**, 120, 1203-12	16.7	471
252	Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. *Arthritis and Rheumatism*, **2009**, 61, 1435-40		81
251	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. *Annals of Hematology*, **2009**, 88, 347-50	3	57
250	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*, **2009**, 23, 215-24	10.7	559

249	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). *Leukemia*, **2009**, 23, 1904-12	10.7	170
248	AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. *Clinical Lymphoma and Myeloma*, **2009**, 9, 80-3		37
247	International prognostic scoring system for Waldenstrom macroglobulinemia. *Blood*, **2009**, 113, 4163-70	2.2	282
246	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. *Blood*, **2009**, 114, 1489-97	2.2	129
245	A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis.. *Blood*, **2009**, 114, 2863-2863	2.2	4
244	Treatment with Oral Melphalan and Dexamethasone of An Extended Patient Population with AL Amyloidosis.. *Blood*, **2009**, 114, 3889-3889	2.2	2
243	High-Sensitivity Troponin Assay Improves the Detection of Cardiac Involvement in AL Amyloidosis and Is the Most Powerful Prognostic Determinant.. *Blood*, **2009**, 114, 1782-1782	2.2	
242	Doxorubicin and congo red effectiveness on prion infectivity in golden Syrian hamster. *Anticancer Research*, **2009**, 29, 2507-12	2.3	5
241	Biomarkers of acute kidney injury. *Advances in Chronic Kidney Disease*, **2008**, 15, 222-34	4.7	131
240	The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. *Journal of Molecular Biology*, **2008**, 378, 887-97	6.5	76
239	Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins. *Molecular Immunology*, **2008**, 45, 1519-24	4.3	1
238	Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). *Biology of Blood and Marrow Transplantation*, **2008**, 14, 6-11	4.7	19
237	Gender-related risk of myocardial involvement in systemic amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2008**, 15, 40-8	2.7	66
236	Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury. *Chest*, **2008**, 134, 101-8	5.3	38
235	Coverage and yield of entry and follow-up screening for tuberculosis among new immigrants. *European Respiratory Journal*, **2008**, 32, 153-61	13.6	45
234	Amyloidosis: is a cure possible?. *Annals of Oncology*, **2008**, 19 Suppl 4, iv63-6	10.3	51
233	Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. *Molecular and Cellular Proteomics*, **2008**, 7, 1570-83	7.6	107
232	Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. *Arthritis and Rheumatism*, **2008**, 58, 1516-20		245

231	Sjögren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity?. *Arthritis and Rheumatism*, **2008**, 58, 1992-9		47
230	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. *Blood*, **2008**, 112, 1689-1689	2.2	3
229	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. *Blood*, **2008**, 112, 869-869	2.2	4
228	Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma. *Cancer Treatment and Research*, **2008**, 142, 211-42	3.5	4
227	The workings of the amyloid diseases. *Annals of Medicine*, **2007**, 39, 200-7	1.5	54
226	Infertility and hypergonadotropic hypogonadism as first evidence of hereditary apolipoprotein A-I amyloidosis. *Journal of Urology*, **2007**, 178, 344-8	2.5	22
225	Genetic microheterogeneity of human transthyretin detected by IEF. *Electrophoresis*, **2007**, 28, 2053-64	3.6	32
224	Metrological sharp shooting for plasma proteins and peptides: The need for reference materials for accurate measurements in clinical proteomics and in vitro diagnostics to generate reliable results. *Proteomics - Clinical Applications*, **2007**, 1, 1016-35	3.1	9
223	Mechanisms of renal damage in plasma cell dyscrasias: an overview. *Contributions To Nephrology*, **2007**, 153, 66-86	1.6	14
222	Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. *Journal of Virology*, **2007**, 81, 4564-71	6.6	15
221	Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. *European Journal of Heart Failure*, **2007**, 9, 808-13	12.3	50
220	Late-onset familial Mediterranean fever: an atypical presentation of dermatologic interest. *Archives of Dermatology*, **2007**, 143, 1080-1		8
219	Transthyretin, nutrition, and inflammation: response to Dr. Bernstein. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45,	5.9	5
218	Bortezomib in the treatment of AL amyloidosis: targeted therapy?. *Haematologica*, **2007**, 92, 1302-7	6.6	78
217	Waldenström macroglobulinemia. *Blood*, **2007**, 109, 5096-103	2.2	150
216	Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. *Blood*, **2007**, 110, 787-8	2.2	156
215	A primer of amyloid nomenclature. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2007**, 14, 179-83	2.7	255
214	Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2007**, 14, 133-40	2.7	26

213	Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45, 419-26	5.9	120
212	Eprodisate for the treatment of renal disease in AA amyloidosis. *New England Journal of Medicine*, **2007**, 356, 2349-60	59.2	177
211	Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. *Protein Science*, **2007**, 16, 343-9	6.3	22
210	Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). *Journal of Clinical Oncology*, **2007**, 25, 8050-8050	2.2	6
209	A Proteomic Approach to the Study of Systemic Amyloidoses **2007**, 360-362		
208	Prognostic Relevance of Serum N-Terminal Pronatriuretic Peptide Type B and Plasma Bnp in Patients with Al Amyloidosis in Dialysis **2007**, 273-274		
207	Clinical Trial for Ttr Amyloidosis Using Diflunisal **2007**, 387-389		
206	Early Harvest Followed by Melphalan-Dexamethasone and second-Line Autologous Stem Cell Transplantation in Al **2007**, 390-392		
205	Keynote Address: Advances in Systemic Amyloidoses **2007**, 341-346		
204	Prolonged Follow-up Study of Al Patients Ineligible for Stem Cell Transplantation Treated with Oral Melphalan and Dexamethasone **2007**, 282-282		
203	Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. *European Heart Journal*, **2006**, 27, 1810	9.5	2
202	Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2006**, 6, 380-3		98
201	Structure, function and amyloidogenic propensity of apolipoprotein A-I. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2006**, 13, 191-205	2.7	111
200	Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. *American Journal of Clinical Nutrition*, **2006**, 83, 350-4	7	45
199	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. *Blood*, **2006**, 107, 3854-8	2.2	209
198	Dangerous small B-cell clones. *Blood*, **2006**, 108, 2520-30	2.2	318
197	Exciting new agents in multiple myeloma. *Blood*, **2006**, 108, 3235-3236	2.2	
196	Refining therapy for AL amyloidosis. *Blood*, **2006**, 108, 3632-3633	2.2	2

195	International uniform response criteria for multiple myeloma. *Leukemia*, **2006**, 20, 1467-73	10.7	1996
194	International Prognostic Scoring System (IPSS) for Waldenstro m Macroglobulinemia (WM).. *Blood* , **2006**, 108, 127-127	2.2	18
193	Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis.. *Blood*, **2006**, 108, 5449-5449	2.2	
192	Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. *Haematologica*, **2006**, 91, 1635-43	6.6	29
191	Therapy and management of systemic AL (primary) amyloidosis. *Swiss Medical Weekly*, **2006**, 136, 715-20	3.1	25
190	Lysozyme: a paradigmatic molecule for the investigation of protein structure, function and misfolding. *Clinica Chimica Acta*, **2005**, 357, 168-72	6.2	61
189	Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. *Protein Science*, **2005**, 14, 696-702	6.3	49
188	Autoantibody activity in Waldenstrom's macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2005**, 5, 225-9		46
187	Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. *Therapeutic Drug Monitoring*, **2005**, 27, 785-92	3.2	72
186	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). *Blood*, **2005**, 105, 2949-51	2.2	180
185	Clinical aspects of systemic amyloid diseases. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2005**, 1753, 11-22	4	169
184	Comparison of three strategies for myocardial protection during coronary artery bypass graft surgery based on markers of cardiac damage. *Clinical Biochemistry*, **2005**, 38, 504-8	3.5	3
183	Proteomics of beta2-microglobulin amyloid fibrils. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2005**, 1753, 23-33	4	34
182	A deiminated viral peptide to detect antibodies in rheumatoid arthritis. *Annals of the New York Academy of Sciences*, **2005**, 1050, 243-9	6.5	10
181	Autologous stem cell and kidney transplantation for primary amyloidosis associated with ESRD: which should come first?. *American Journal of Transplantation*, **2005**, 5, 1585-6	8.7	5
180	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. *American Journal of Hematology*, **2005**, 79, 319-28	7.1	971
179	A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. *Annals of Neurology*, **2005**, 58, 639-44	9.4	72
178	Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3680-6	12.7	64

177	Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. *Journal of Clinical Oncology*, **2005**, 23, 4662-8	2.2	64
176	Paraprotein interference in an assay of conjugated bilirubin. *Clinical Chemistry*, **2005**, 51, 1076-7	5.5	17
175	Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2005**, 12, 120-6	2.7	40
174	Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2005**, 12, 1-4	2.7	274
173	Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. *Clinical Cancer Research*, **2005**, 11, 1786-90	12.9	54
172	Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?. *Rheumatology*, **2005**, 44, 1074-5	3.9	47
171	Heavy chain disease can be detected by capillary zone electrophoresis. *Clinical Chemistry*, **2005**, 51, 247-9	5.5	16
170	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2005**, 12, 159-63		1
169	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2005**, 12, 159-163		2
168	How we treat Waldenstrm's macroglobulinemia. *Haematologica*, **2005**, 90, 117-25	6.6	11
167	Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". *Current Medicinal Chemistry*, **2004**, 11, 1065-84	4.3	44
166	Amyloidosis and Waldenstrm's macroglobulinemia. *Hematology American Society of Hematology Education Program*, **2004**, 2004, 257-82	3.1	65
165	Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma. *Immunology*, **2004**, 112, 420-7	7.8	12
164	The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. *Journal of Internal Medicine*, **2004**, 255, 159-78	10.8	172
163	First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. *Arthritis and Rheumatism*, **2004**, 50, 2966-9		61
162	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. *Gastroenterology*, **2004**, 126, 1416-22	13.3	59
161	Immune mechanisms of AL amyloidosis. *Drug Discovery Today Disease Mechanisms*, **2004**, 1, 365-373		6
160	Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2004**, 1690, 33-41	6.9	15

159	Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. *Blood*, **2004**, 103, 2936-8	2.2	316
158	Sharpening therapeutic strategy in AL amyloidosis. *Blood*, **2004**, 104, 1593-1594	2.2	
157	MYOCARDIAL SYSTOLIC DYSFUNCTION IN CARDIAC AL AMYLOIDOSIS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION. *Journal of Hypertension*, **2004**, 22, S174-S175	1.9	0
156	Experience with a Patient-Adapted Approach to Autologous Peripheral Blood Stem Cell Transplantation in Al Amyloidosis **2004**, 109-111		
155	Definition of Organ Involvement and Treatment Response in Primary Systemic Amyloidosis (AL): A Consensus Opinion from the 10TH International Symposium on Amyloid and Amyloidosis **2004**, 151-153		1
154	Thalidomide plus Intermediate-Dose Dexamethasone in Refractory/Relapsed Al Patients **2004**, 115-117		
153	Amyloid versus Non-Amyloid Immunoglobulin Deposits **2004**, 133-135		
152	Human Monoclonal Cryocrystalglobulinemia: First Complete Heavy and Light Chain Variable Region Nucleotide Sequences.. *Blood*, **2004**, 104, 1381-1381	2.2	
151	Uncommon Conditions Underlying AA Amyloidosis **2004**, 521-523		
150	Amyloid Versus Non-Amyloid Immunoglobulin Deposits **2004**, 133-135		
149	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). *Haematologica*, **2004**, 89, 717-41	6.6	41
148	Systemic amyloidosis: are we moving ahead?. *Netherlands Journal of Medicine*, **2004**, 62, 104-5	0.5	7
147	Molecular mechanisms of amyloidosis. *New England Journal of Medicine*, **2003**, 349, 1872-3; author reply 1872-3	59.2	15
146	Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. *Seminars in Oncology*, **2003**, 30, 116-20	5.5	254
145	Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. *Seminars in Oncology*, **2003**, 30, 211-5	5.5	80
144	Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. *Journal of Investigative Dermatology*, **2003**, 121, 308-14	4.3	21
143	Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. *Clinical Chemistry*, **2003**, 49, 1554-5	5.5	50
142	Utility of biochemical markers in the follow-up of heart transplant recipients. *Transplantation Proceedings*, **2003**, 35, 3075-8	1.1	10

141	Molecular mechanisms of amyloidosis. *New England Journal of Medicine*, **2003**, 349, 583-96	59.2	1335
140	Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. *Circulation*, **2003**, 107, 2440-5	16.7	390
139	Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. *Journal of Biological Chemistry*, **2003**, 278, 2444-51	5.4	75
138	4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. *FASEB Journal*, **2003**, 17, 803-9	0.9	103
137	Guidelines for the analysis of Bence Jones protein. *Clinical Chemistry and Laboratory Medicine*, **2003** , 41, 338-46	5.9	37
136	Topological investigation of amyloid fibrils obtained from beta2-microglobulin. *Protein Science*, **2002**, 11, 2362-9	6.3	49
135	Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?. *British Heart Journal*, **2002**, 88, 615-21		28
134	Hereditary amyloidosis. *New England Journal of Medicine*, **2002**, 347, 1206-7; author reply 1206-7	59.2	17
133	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2002**, 9, 108-114	2.7	115
132	A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2002**, 9, 24-30	2.7	42
131	Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. *Blood*, **2002**, 100, 948-53	2.2	130
130	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2002**, 9, 108-14	2.7	29
129	A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. *British Journal of Haematology*, **2001**, 113, 1044-6	4.5	61
128	Holter monitoring in AL amyloidosis: prognostic implications. *PACE - Pacing and Clinical Electrophysiology*, **2001**, 24, 1228-33	1.6	97
127	Perturbations of the Kepler Problem in Global Coordinates: A Program. *Celestial Mechanics and Dynamical Astronomy*, **2001**, 81, 313-319	1.4	1
126	Biological features of the clone involved in primary amyloidosis (AL). *Leukemia*, **2001**, 15, 195-202	10.7	16
125	Protein aggregation. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 1065-75	5.9	23
124	A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. *Journal of Biological Chemistry*, **2001**, 276, 46714-21	5.4	124

123	The Pavia approach to clinical protein analysis. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 1025-8	5.9	14
122	Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. *Protein Science*, **2001**, 10, 187-99	6.3	42
121	Therapeutic advances demand accurate typing of amyloid deposits. *American Journal of Medicine*, **2001**, 111, 243-4	2.4	40
120	Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. *American Journal of Pathology*, **2001**, 158, 1599-603	5.8	27
119	Nodular macroglossia with combined light chain and beta-2 microglobulin deposition in a long-term dialysis patient. *Journal of Nephrology*, **2001**, 14, 128-31	4.8	3
118	Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel hot spot' in codon 47. *Clinical Genetics*, **2000**, 57, 284-90	4	9
117	The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation. *Biochemical Journal*, **2000**, 351, 273-9	3.8	16
116	The molecular interaction of 4?-iodo-4?-deoxydoxorubicin with Leu-55Pro transthyretin amyloid-like oligomer leading to disaggregation. *Biochemical Journal*, **2000**, 351, 273-279	3.8	39
115	Serum amyloid A, procalcitonin, and C-reactive protein in early assessment of severity of acute pancreatitis. *Digestive Diseases and Sciences*, **2000**, 45, 1072-8	4	34
114	Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation. *Protein Science*, **2000**, 9, 831-45	6.3	242
113	Conformational dynamics of the beta2-microglobulin C terminal in the cell-membrane-anchored major histocompatibility complex type I. *Cellular and Molecular Life Sciences*, **2000**, 57, 675-83	10.3	3
112	Procalcitonin Is Not a Reliable Marker for the Assessment of Severity in Acute Pancreatitis without Infectious Complications. *Clinical Chemistry*, **2000**, 46, 428-430	5.5	12
111	Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability. *Journal of Structural Biology*, **2000**, 130, 280-9	3.4	156
110	4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. *American Journal of Pathology*, **2000**, 156, 1919-25	5.8	44
109	Procalcitonin is not a reliable marker for the assessment of severity in acute pancreatitis without infectious complications. *Clinical Chemistry*, **2000**, 46, 428-30	5.5	5
108	Clotting alterations in primary systemic amyloidosis. *Haematologica*, **2000**, 85, 289-92	6.6	30
107	Treatment of AL Amyloidosis with 4?-Iodo-4?-Deoxydoxorubicin: An Update. *Blood*, **1999**, 93, 1112-1113	2.2	39
106	Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. *Bone Marrow Transplantation*, **1999**, 23, 323-7	4.4	17

105	Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1999**, 6, 273-7	2.7	14
104	The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. *American Journal of Pathology*, **1999**, 155, 695-702	5.8	101
103	Aprotinin 99mTc Myocardial Scan: Risk Stratification of Cardiac Events in Patients with Al/Attr Amyloidosis **1999**, 479-482		
102	Treatment of AL amyloidosis with 4'-lodo-4'-deoxydoxorubicin: an update. *Blood*, **1999**, 93, 1112-3	2.2	9
101	The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. *Haematologica*, **1999**, 84, 218-21	6.6	34
100	Beta2-microglobulin can be refolded into a native state from ex vivo amyloid fibrils. *FEBS Journal*, **1998**, 258, 61-7		98
99	Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. *European Journal of Nuclear Medicine and Molecular Imaging*, **1998**, 25, 701-8	8.8	38
98	Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. *Kidney International*, **1998**, 54, 650-71	9.9	205
97	Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. *Journal of Hepatology*, **1998**, 29, 879-86	13.4	12
96	Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven Selection. *Blood*, **1998**, 91, 2948-2954	9.2	47
95	Evidence that amyloidogenic light chains undergo antigen-driven selection. *Blood*, **1998**, 91, 2948-54	2.2	9
94	Symposium on Amyloid Cardiomyopathy: Diagnosis and Treatment, Pavia, September 21, 1996. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1997**, 4, 296-299	2.7	
93	Light and electron microscopy immunohistochemical characterization of amyloid deposits. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1997**, 4, 157-170	2.7	45
92	Biology and therapy of immunoglobulin deposition diseases. *Hematology/Oncology Clinics of North America*, **1997**, 11, 89-110	3.1	39
91	Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils. *FEBS Journal*, **1997**, 249, 21-6		22
90	Imaging of Myocardial Amyloid Involvement with 99m Tc Aprotinin **1997**, 191-196		
89	Monoclonal gammapathies. *Journal of the International Federation of Clinical Chemistry*, **1997**, 9, 171-6		5
88	Functional study of autonomic neuropathy in primary (AL) amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1996**, 3, 167-172	2.7	1

87	Neuropathies associated with monoclonal gammopathies. *Neuromuscular Disorders*, **1996**, 6, 3-18	2.9	54
86	Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1996**, 1317, 161-7	6.9	16
85	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. *Nephrology Dialysis Transplantation*, **1996**, 11, 1708-1711	4.3	3
84	Current concepts on the pathogenesis of systemic amyloidosis. *Nephrology Dialysis Transplantation*, **1996**, 11 Suppl 9, 53-62	4.3	22
83	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. *Nephrology Dialysis Transplantation*, **1996**, 11, 1708-1711	4.3	5
82	Utility of bisphosphonates in treating bone metastases. *Medical Oncology*, **1996**, 13, 215-21	3.7	4
81	Inverse polymerase chain reaction for cloning complete human immunoglobulin variable regions and leaders conserving the original sequence. *Analytical Biochemistry*, **1996**, 239, 107-9	3.1	17
80	Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. *British Journal of Haematology*, **1996**, 93, 789-94	4.5	75
79	Pavia, Italy Symposium. Recent Developments in Amyloidosis, June 1, 1995. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1996**, 3, 57-58	2.7	
78	Familial AL-amyloidosis in three Italian siblings. *Haematologica*, **1996**, 81, 105-9	6.6	6
77	Reduced taste perception in AL amyloidosis. A frequently unnoticed sensory impairment. *Haematologica*, **1996**, 81, 110-5	6.6	4
76	Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. *European Journal of Nuclear Medicine and Molecular Imaging*, **1995**, 22, 1393-401		68
75	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. *Blood*, **1995**, 86, 855-861	2.2	117
74	Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 2959-63	11.5	173
73	Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. *American Heart Journal*, **1995**, 130, 528-36	4.9	40
72	The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils. *Journal of Internal Medicine*, **1995**, 237, 143-9	10.8	11
71	Characterization of the Two Unique Human Anti-Flavin Monoclonal Immunoglobulins. *FEBS Journal*, **1995**, 228, 886-893		
70	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. *Blood*, **1995**, 86, 855-61	2.2	20

69	Treatment of primary amyloidosis. *Seminars in Hematology*, **1995**, 32, 60-79	4	43
68	Characterization of the two unique human anti-flavin monoclonal immunoglobulins. *FEBS Journal*, **1995**, 228, 886-93		6
67	Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. *Haematologica*, **1995**, 80, 409-15	6.6	19
66	Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. *Blood*, **1994**, 83, 2939-2945	2.2	104
65	A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma. *International Journal of Oncology*, **1994**, 5, 833-9	1	6
64	Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. *American Journal of Hematology*, **1994**, 46, 189-93	7.1	32
63	Neuropathies associated with monoclonal gammapathies. *Haematologica*, **1994**, 79, 557-66	6.6	18
62	Application of monoclonal anti-idiotypes in the study of AL amyloidosis: therapeutic implications. *Renal Failure*, **1993**, 15, 365-71	2.9	1
61	Primary (AL) amyloidosis. *Renal Failure*, **1993**, 15, 429-33	2.9	6
60	Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro. *Cancer Chemotherapy and Pharmacology*, **1993**, 31, 265-8	3.5	9
59	Acute phase proteins and prognosis in multiple myeloma. *British Journal of Haematology*, **1993**, 83, 595-601	4.5	40
58	Occurrence of monoclonal components in general practice: clinical implications. *European Journal of Haematology*, **1992**, 48, 192-5	3.8	38
57	Use of an anti-idiotypic monoclonal antibody in studying amyloidogenic light chains in cells, urine and fibrils: pathophysiology and clinical implications. *Scandinavian Journal of Immunology*, **1992**, 36, 607-15	3.4	7
56	Gene expression of pyrogenic cytokines in Hodgkin's disease lymph nodes. *Haematologica*, **1992**, 77, 221-5	6.6	3
55	A plea to overcome the concept of "staging" and related inadequacy in multiple myeloma. *European Journal of Haematology*, **1991**, 46, 177-81	3.8	7
54	Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1991**, 1097, 177-82	6.9	20
53	Amino acid sequence of the FV region of a human monoclonal IgM (NOV) with specificity for the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1, which cross-reacts with polynucleotides and with denatured DNA. *Journal of Immunology*, **1991**, 147, 915-20	5.3	5
52	Immunochemical characteristics of a particular cryoglobulin. A new cryoglobulin subgroup?. *Clinical and Experimental Rheumatology*, **1991**, 9, 399-402	2.2	2

51	High Molecular Weight Proteins, Sensitive to Collagenase Digestion are Intimate Constituents of Amyloid Deposits **1991**, 519-522		1
50	Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro. *Medical Oncology and Tumor Pharmacotherapy*, **1991**, 8, 265-9		2
49	A case of IgM(kappa) monoclonal gammopathy simulating an IgM-IgG biclonal gammopathy. *Annals of Clinical Biochemistry*, **1990**, 27 (Pt 2), 158-60	2.2	
48	Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. *British Journal of Haematology*, **1990**, 74, 65-9	4.5	62
47	Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. *Hematological Oncology*, **1990**, 8, 23-30	1.3	53
46	The second riboflavin-binding myeloma IgG lambdaDOT. I. Biochemical and functional characterization. *Molecular Immunology*, **1990**, 27, 385-94	4.3	11
45	The Merlini, Waldenstrm, Jayakar staging system revisited. *European Journal of Haematology*, **1989**, 51, 105-10	3.8	2
44	Treatment of painful bone lesions and hypercalcemia. *European Journal of Haematology*, **1989**, 51, 135-9	3.8	13
43	Structural characterization of kappa II Inc, a new amyloid immunoglobulin. *BBA - Proteins and Proteomics*, **1989**, 995, 103-8		9
42	Study of three patients with monoclonal gammopathies and 'lupus-like' anticoagulants. *British Journal of Haematology*, **1989**, 73, 221-7	4.5	55
41	The laboratory investigation of monoclonal components. *Haematologica*, **1988**, 73, 79-85	6.6	5
40	Hepatitis B virus markers in monoclonal (type I and II) and polyclonal (type III) cryoglobulinemias. *Haematologica*, **1988**, 73, 375-8	6.6	7
39	Selective bone marrow involvement of lymphoplasmacytic cells secreting monoclonal IgA rheumatoid factor in a patient with Sjgren's syndrome and serum hyperviscosity. *Annals of the Rheumatic Diseases*, **1987**, 46, 938-42	2.4	5
38	Serum Thymidine Kinase and Beta-2 Microglobulin in Monoclonal Gammopathies. *Tumori*, **1987**, 73, 445-449	1.7	9
37	Multiple myeloma and related plasma cell dyscrasias. *JAMA - Journal of the American Medical Association*, **1987**, 258, 2930-7	27.4	5
36	A sulfhydryl-rich IgM protein with multiple serological specificities. *Clinical and Experimental Immunology*, **1987**, 69, 148-56	6.2	1
35	Complete remission in plasma cell leukaemia. *British Journal of Haematology*, **1986**, 62, 525-7	4.5	16
34	Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. *European Journal of Cancer & Clinical Oncology*, **1986**, 22, 787-91		10

33	Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. *Seminars in Oncology*, **1986**, 13, 350-65	5.5	61
32	The clinical implications of monoclonal immunoglobulins. *Seminars in Oncology*, **1986**, 13, 366-79	5.5	31
31	Peptichemio, Vincristine, Prednisone Induction Treatment in Multiple Myeloma. *Tumori*, **1985**, 71, 581-588	1.7	4
30	Alpha heavy chain disease: report of two cases. *Haematologica*, **1985**, 70, 431-6	6.6	3
29	Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio. *Cancer Treatment Reports*, **1985**, 69, 971-5		8
28	Peptichemio, vincristine, prednisone induction treatment in multiple myeloma. *Tumori*, **1985**, 71, 581-8	1.7	2
27	A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. *Journal of Clinical Immunology*, **1984**, 4, 185-96	5.7	31
26	Micropolyspora faeni antigens of three commercial extracts. *Mycopathologia*, **1984**, 84, 165-9	2.9	3
25	Differential transplacental binding of valproic acid: influence of free fatty acids. *British Journal of Clinical Pharmacology*, **1984**, 17, 759-62	3.8	9
24	Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. *European Journal of Cancer & Clinical Oncology*, **1984**, 20, 81-90		9
23	Mechanism of altered drug binding to serum proteins in pregnant women: studies with valproic acid. *Therapeutic Drug Monitoring*, **1984**, 6, 25-30	3.2	26
22	Proliferative activity, response to therapy and survival in multiple myeloma. *Haematologica*, **1984**, 69, 148-62	6.6	5
21	Identification of specific plasma proteins determining the agarose gel electrophoresis by the immunosubtraction technique. *Clinical Chemistry and Laboratory Medicine*, **1983**, 21, 841-4	5.9	
20	Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery. *Metabolism: Clinical and Experimental*, **1982**, 31, 1100-4	12.7	26
19	Calcium antagonists and hormone release. IV. The role of calcium in glucose-stimulated early phase insulin release in vivo. *Journal of Endocrinological Investigation*, **1982**, 5, 121-4	5.2	2
18	Serum alpha-1-acid-glycoprotein, haptoglobin and C3 in Hodgkin's disease. A comparison with other acute-phase indicators. *Acta Haematologica*, **1982**, 67, 255-62	2.7	2
17	Peptichemio induction therapy in myelomatosis. *Cancer Chemotherapy and Pharmacology*, **1982**, 8, 9-16	3.5	13
16	Detection and identification of monoclonal components: immunoelectrophoresis on agarose gel and immunofixation on cellulose acetate compared.. *Clinical Chemistry*, **1981**, 27, 1862-1865	5.5	19

15	Multivariate statistical analysis of quantitative serum protein data in populations of Rwanda. *American Journal of Physical Anthropology*, **1981**, 55, 13-20	2.5	0
14	Electrophoresis: cellulose acetate vs agarose gel, visual inspection vs densitometry. *Clinical Chemistry*, **1981**, 27, 1944-5	5.5	2
13	Clinical usefulness of the molecular interpretation of the cellulose acetate serum protein electrophoresis (preliminary communication). *Research in Clinic and Laboratory*, **1980**, 10, 239-42		
12	Treatment of multiple myeloma with vincristine. *Acta Haematologica*, **1980**, 64, 176-8	2.7	1
11	A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. *Blood*, **1980**, 55, 1011-1019	2.2	103
10	Vincristine in the treatment of multiple myeloma. *Haematologica*, **1980**, 65, 595-611	6.6	4
9	A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. *Blood*, **1980**, 55, 1011-9	2.2	16
8	An IgM monoclonal protein with multiple serological specificities. *Clinical and Experimental Immunology*, **1979**, 37, 276-82	6.2	7
7	Waldenstrm's macroglobulinemia/lymphoplasmacytic lymphoma138-154		
6	Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma190-215		
5	WALDENSTRM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA129-149		
4	Anatomic and Clinical Clues to In Vivo Mechanisms of Amyloidogenesis29-46		
3	Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain (AL) amyloidosis patient		2
2	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma207-227		
1	Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*,1-13	2.7	5